Cornea

Patient centricity an important driver in topical development.

According to researchers, using nanoparticles to encapsulate eye medication decreased graft rejection while requiring fewer and smaller doses.

Physicians making sense of the cornea transplant alphabet soup.

Medical student’s vision was threatened by keratoconus, and early diagnosis and treatment could prove to be key to preserving the patient’s vision.

Look for fluctuating vision, test objectively and keep a few effective tools at your disposal to treat OSD.

Kamran M. Riaz, MD, a clinical associate professor and director of Medical Student Research at the Dean A. McGee Institute at the University of Oklahoma, recently discussed with Ophthalmology Times some of the latest trends in cornea treatment.

According to James Chodosh MD, MPH, some corneal conditions may not be treatable with a transplant.

Stromal regeneration seems possible in patients with keratoconus.

The technology will be available soon for ophthalmologists in select countries across Asia Pacific and Europe.

Eye care providers must look beyond visual acuity in screening for disease.

The Keralink Trial was the first randomized clinical trial that tested the hypothesis that corneal cross-linking (CXL) might decrease keratoconus progression in children compared with the use of spectacles or contact lenses.

The Keralink Trial was the first randomized clinical trial that tested the hypothesis that corneal cross-linking (CXL) might decrease keratoconus progression in children compared with the use of spectacles or contact lenses.

Corneal neurotization is an efficacious procedure to restore sensation to a neurotrophic cornea, involving the surgical transfer of sensory nerve fibers to the cornea.

CEO and cofounder of the International Keratoconus Academy S. Barry Eiden, OD, FAAO, FSLS, sits down to discuss the inaugural symposium, which will be held April 22-23, 2023, in Scottsdale, Arizona.

Over the years, IKA has become an invaluable resource for eye care professionals.

After comparing two techniques of corneal transplant tissue preparation, research shows a newer, faster technique is safe and effective.

Three recipients will each receive up to $10,000 toward their research on a 1-year project that can go toward additional training in specialty equipment or research methodologies.

Recent research suggests the need for routine HSV-1 and VZV PCR testing in all explanted corneas regardless of clinical suspicion to detect, treat, and prevent possible recurrence of herpes infection in corneal grafts and support graft survival.

Stephen Pflugfelder, MD, professor and director of the Ocular Surface Center at Baylor College of Medicine in Houston, Texas, presents a challenging diagnostic dilemma.

Patients need to pay attention to their eye health over the long term.

Members of the Ophthalmology Times Europe® Editorial Advisory Board were asked to predict developments in their ophthalmic specialties and interests for 2023. A focus is our ageing population, while efficiency and productivity are also on their minds. The board members agree that one of the major challenges in the year to come will be the large number of patients awaiting diagnosis and treatment, which is only going to increase with the rising average life expectancy worldwide.

CXL has been proven effective to treat patients with corneal ectasias.

Receiving FDA orphan drug designation allows the company to proceed with plans to advance the development of BRM424, a novel, first-in-class, potential treatment for neurotrophic keratitis.

According to the company, the NDA is supported by positive phase data demonstrating the rapid reversal of dilated eyes and favorable safety profile in pediatric and adult subjects.

The company is rolling out the Biovance 3L ocular tri-layer human amniotic membrane.